News Releases 2013
New Production Facility for Bone-graft Substitute Medical Devices Commences Operations
Bone-graft Substitute with Unidirectional Porous Hydroxyapatite
August 8, 2013
Kuraray Co., Ltd.
Kuraray Co., Ltd. (Headquarters: Chiyoda-ku, Tokyo; President: Fumio Ito; hereafter "Kuraray") announces the completion and commencement of operations of a new production facility for bone-graft substitute medical devices REGENOS at its Kurashiki Plant (Kurashiki City, Okayama Prefecture; General Manager: Hirohide Hayashi).
Overview of REGENOS Production Facilities
||Kuraray Kurashiki Plant (7471, Tamashimaotoshima, Kurashiki City, Okayama Prefecture 713-8550, Japan)
||100,000 units per year
- Features of REGENOS
- Porous structure allows easy ingrowth by living tissue
- Made of hydroxyapatite, the major component of living bone, the unidirectional porous structure allows blood and bone cells to easily penetrate the material.*
- *By volume, 75% of the overall REGENOS structure consists of pores, and over 55% of the total material comprises pores larger than 30 μm in diameter. The aligned connectivity and porous structure of the material are suitable for bone union with surrounding living bone and bone ingrowth into the interior spaces of the graft.
μCT scan image
Going forward, Kuraray will work to improve patients’ quality of life through the expansion of its bone-graft substitute REGENOS business.
- ■A bone-graft substitute is a product used for medical treatment used when a bone transplant becomes necessary as a result of disease or injury to the natural bone.
At present, autogenous bone grafts are the predominant type of bone transplant in Japan. Aiming to reduce the burden placed on patients by offering an alternative to autogenous bone grafts, Kuraray is developing REGENOS that can be used to fill in for bone defect and aid in the regeneration of bone.
The development of Kuraray's bone-graft substitute medical devices was announced in a press release available at http://www.kuraray.co.jp/en/release/2009/090820.html.
After obtaining approval to manufacture and market bone-graft substitute medical devices in 2009, Kuraray began small-scale production at its Kurashiki Research Center.